Coronary artery disease (CAD) is a major cause of morbidity and mortality in SLE, including the Hopkins Lupus Cohort. Currently, 9% of the cohort have had clinical evidence (angina or myocardial infarction) of CAD. In our initial prospective study we found that duration of prednisone, hypertension, hyperlipidemia and obesity were risk factors for later CAD. We can now extend that list to include age, male sex, elevated homocysteine, renal insufficiency and antiphospholipid antibodies. Many of the risk factors are amenable to intervention, but the timing of intervention, and the effectiveness of intervention, must be determined.
Urowitz MB , Bookman AAM , Koehler BE et al. The bimodal mortality pattern of systemic lupus erythematosus . Am J Med1976; 60: 221-225 .
2.
Bulkley BH , Roberts WC . The heart in systemic lupus erythematosus and the changes induced in it by corticosteroid therapy: a study of 36 necropsy patients . Am J Med1975; 58: 243-264 .
3.
Tan EM , Cohen AS , Fries JF et al. The 1982 revised criteria for the classification of systemic lupus erythematosus . Arthritis Rheum1982; 25: 1271-1277 .
4.
Hochberg MC . Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus [letter] . Arthritis Rheum1997; 40: 1725-1725 .
5.
Gladman D , Ginzler E , Goldsmith C et al. The development and initial validations of the Systemic Lupus International Collaborating Clinics/American College Rheumatology damage index for systemic lupus erythematosus . Arthritis Rheum199639: 363-369 .
6.
Petri M , Rheinschmidt M , Whiting-O'Keefe Q et al. The frequency of lupus anticoagulant in systemic lupus erythematosus: a study of 60 consecutive patients by activated partial thromboplastin time, Russell viper venom time, and anticardiolipin antibody . Ann Int Med1987; 106: 524-531 .
7.
Petri M , Nelson L , Weimer F et al. The automated modifid Russell viper venom time test for the lupus anticoagulant . J Rheumatol1991; 18: 1823-1825 .
8.
Petri M , Perez-Gutthann S , Spence D , Hochberg MC . Risk factors for coronary artery disease in patients with systemic lupus erythematosus . Am J Med1992; 93: 513-519 .
9.
Petri M , Lakatta C , Magder L , Goldman DW . Effect of prednisone and hydroxychloroquine on coronary artery disease risk factors in systemic lupus erythematosus: a longitudinal data analysis . Am J Med1994; 96: 254-259 .
10.
Petri M . Hydroxychloroquine used in the Baltimore Lupus Cohort: effects on lipids, glucose and thrombosis . Lupus1996; 5 (Suppl. 1): S16-S22 .
11.
Petri M . Hydroxychloroquine: past, present, future [editorial] . Lupus19987: 65-67 .
12.
Petri M , Roubenoff R , Dallal GE et al. Plasma homocysteine as a risk factor for atherothrombotic events in systemic lupus erythematosus . Lancet1996; 348: 1120-1124 .
13.
Petri M , Vu D , Omura A et al. Effectiveness of B-vitamin therapy in reducing plasma total homocysteine in patients with systemic lupus [abstract] . Arthritis Rheum1998; 41 (9 (Suppl.)): S241-S241 .
14.
Alarcón-Segovia D , Delezé M , Oria CV et al. Antiphospholipid antibodies and the antiphospholipid syndrome in systemic lupus erythematosus: a prospective analysis of 500 consecutive patients . Medicine1989; 68: 353-374 .
15.
Hamsten A , Norberg R , Björkholm M et al. Antibodies to cardiolipin in young survivors of myocardial infarction: an association with recurrent cardiovascular events . Lancet1986; 1: 113-116 .
16.
Petri M . Epidemioloyg of the antiphospholipid syndrome. In: Asherson RA , Cervera R , Piette J-C , Shoenfeld Y (eds). The Antiphospholipid SyndromeCRC Press: Boca Raton, FL1996, 13-28.
17.
Hasunuma Y , Matsuura E , Makita Z et al. Involvement of b2-glycoprotein I and anticardiolipin antibodies in oxidatively modified low-density lipoprotein uptake by macrophages . Clin Exp Immunol1997; 107: 569-573 .
18.
Petri M . Thrombosis and systemic lupus erythematosus: the Hopkins Lupus Cohort perspective . Scand J Rheumatol1996; 25: 191-193 .
19.
Petri M , Zonana-Nacach A , Barr S , Magder L . Damage in systemic lupus erythematosus is dependent on dose and mode of delivery of corticosteroid [abstract] . Arthritis Rheum1999; 42 (Suppl): S97-S97 .
20.
Manzi S , Selzer F , Sutton-Tyrrell K et al. Prevalence and risk factors of carotid plaque in women with systemic lupus erythematosus . Arthritis Rheum1999; 42: 51-60 .
21.
Petri M , Hamper U . Frequency of atherosclerosis detected by carotid duplex in SLE [abstract] . Arthritis Rheum1997; 40: No. 9 Suppl.: S219-S219 .
22.
Petri M , Civelek C . Discordance of myocardial SPECT and carotid duplex in systemic lupus erythematosus (SLE) . Arthritis Rheum1998; 41: No. 9 Suppl.: S.
23.
Manzi S , Meilahn EN , Raire JE et al. Age-specific incidence rates of myocardial infarction and angina in women with systemic lupus erythematosus: comparison with the Framingham Study . Am J Epidemiol1997; 145 (5): 408-415 .
Wallace DJ , Podell T , Weiner J et al. Systemic lupus erythematosus-survival patterns: experience with 609 patients . J Am Med Assoc1981; 245: 934-938 .
26.
Rosner S , Ginzler EM , Diamond HS et al. A multicenter study of outcome in systemic lupus erythematosus. II. Causes of death . Arthritis Rheum1982; 25: 612-617 .
27.
Helve T . Prevalence and mortality rates of systemic lupus erythematosus and causes of death in SLE patients in Finland . Scand J Rheumatol1985; 14: 43-46 .
28.
Rubin LA , Urowitz MB , Gladman DD . Mortality in systemic lupus erythematosus: the bimodal pattern revisited . Q J Med1985; 55: 87-98 .
29.
Jonsson H , Hived O , Sturfelt G . Outcome in systemic lupus erythematosus: a prospective study of patients from a defined population . Medicine1989; 68: 141-150 .
30.
Shome GP , Sakauchi M , Yamane K et al. Ischemic heart disease in systemic lupus erythematosus. A retrospective study of 65 patients treated with prednisone . Japan J Med1989; 28: 599-603
31.
Reveille JS , Bartolucci A , Alarcón GS . Prognosis in systemic lupus erythematosus: negative impact of increasing age at onset, black race, and thrombocytopenia, as well as causes of death . Arthritis Rheum1990; 33: 37-48 .
32.
Pistiner M , Wallace DJ , Nessim S et al. Lupus erythematosus in the 1980s: a survey of 570 patients . Arthritis Rheum1991; 21: 55-64 .
33.
Abu-Shakra M , Urowitz MB , Gladman DD , Gough J . Mortality studies in systemic lupus erythematosus. Results from a single center. I. Causes of death . J Rheumatol1995; 22: 1259-1264 .
34.
Ward MM , Pyun E , Studenski S . Causes of death in systemic lupus erythematosus . Arthritis Rheum1995; 38: 1492-1499 .
35.
Bidani AK , Roberts JL , Schwartz M , Lewis EJ . Immunopathology of cardiac lesions in fatal systemic lupus erythematosus . Am J Med1980; 69: 849-858 .
36.
Godeau P , Guilleven L , Fechner J et al. Manifestations cardiques du lupus erythemateaux aigu dissemine . Nouv Presse Med1981; 10: 2175-2178 .
37.
Haider YS , Roberts WC . Coronary arterial disease in systemic lupus erythematosus: quantification of degree of narrowing in 22 necropsy patients (21 women) aged 16 to 37 years . Am J Med1981; 70: 775-781 .
Hearth-Holmes M , Baethge BA , Broadwell L , Wolf RE . Dietary treatment of hyperlipidemia in patients with systemic lupus erythematosus . J Rheumatol1995; 22: 450-454 .
40.
Sturfelt G , Eskilsson J , Nived O et al. Cardiovascular disease in systemic lupus erythematosus: a study of 75 patients from a defined population . Medicine1992; 71: 216-223 .
41.
Hospenpud JD , Montanaro A , Hart MV et al. Myocardial perfusion abnormalities in asymptomatic patients with systemic lupus erythematosus . Am J Med1984; 77: 286-292 .
42.
Leung W-H , Wong K-L , Lau C-P et al. Cardiac abnormalities in systemic lupus erythematosus: a prospective M-mode, cross-sectional and Doppler echocardiographic study . Int J Cardiol1990; 27: 367-375 .
